Opdualag
Active substance: nivolumab, relatlimab
nivolumab, relatlimab
Centralised EU authorisationActive
Marketing holder: Bristol-Myers Squibb Pharma EEIG
Verified 2026-10-09 · EMA
Analogues in other countries- Source: EMA
- Countries with the substance registered: 3
Composition
Products containing nivolumab in other countries
Showing products with this active substance, combinations included; the full composition is shown for each product.
| Country | Products |
|---|---|
| RU 3 |
|
| US 7 |
|
Import and control
Control by country
- Russiaprescription only
Source: GRLS (Russian state register) · record 01a120c3-3560-793b-a6a7-2d72e94106e7,01a120c3-f256-7f44-8d8f-5645fc3e91e1,01a120c5-1c85-76ef-af22-38e0898f4cbd;count=3 · valid from 2026-10-09 · verified 2026-10-09
- United Statesprescription only
Source: openFDA NDC · record 01a1208d-013c-7ee8-96c0-614f2c99b389,01a1208d-0164-78d7-a14e-255bc8bce769,01a12091-747d-7ba6-9fd3-27f9901aaaee,01a1209c-ff8d-79fb-b54c-d06be16e6d5a;count=4 · valid from 2026-10-09 · verified 2026-10-09
Registration
- Registration number
- EMEA/H/C/005481
- Registration status
- Active
- ATC code
- L01FY02
Sources
- product · EMA · EMEA/H/C/005481 · Verified 2026-10-09
- registration_status · EMA · EMEA/H/C/005481 · Verified 2026-10-09
- ingredients.0 · EMA · EMEA/H/C/005481 · Verified 2026-10-09
- ingredients.1 · EMA · EMEA/H/C/005481 · Verified 2026-10-09